Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

COSCIENS Biopharma Inc T.AEZ

Primary Symbol: T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

Bullboard Posts

Comment by slagheapon Aug 18, 2015 4:11pm

215 Views

Post# 24029219

RE:RE:RE:what a disaster

AEterna Zentaris: CEO Says Stay Away, You Should Listen

Must Read | Aug. 17, 2015 2:21 PM ET | seekingalpha

Summary

Dodd: "Dilution attributable to warrants [...] is the reason for the pressure on our stock price and [...] such dilution could continue for the next several months".
AEterna has declined 66% since my May article due to the alphabet soup of warrants issued in the company's March offerings, declining 20% after the company's quarterly update call Friday.
Potential shares from series B warrants based on VWAP: $0.145 (Friday's close, 232,909,939), $0.10 (356,529,412), or $0.05 (754,858,824).
While it's positive the DSMB update will be in October for ZoptEC, we will not get any definitive readouts to determine trial success/failure for late-stage assets until late 2016.
With more than 70% of the series B warrants not exercised as of August 12th, shares will remain pressured, as potential dilution from these warrants spirals out of control.